This brings a basic research question: Could a more specific targeting of Hsp90 via modulation of PTMs or PTM-causing enzymes be a revolutionary therapeutic method for a variety of diseases where Hsp90 plays a role including cardiomyopathy? Here, HSP90AA1 is linked to cardiomyopathy.